The Fund Grade · free · no account needed

What grade does DODGX get?

Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.

F

Fundprints Fund Grade · as of 2026-09-01

Dodge & Cox Stock

#404 of 440 graded active funds · value · large segment peer group

The point · specialist footprint

DODGX puts less of its book behind proven specialists than 62% of graded funds.

Bottom 20%

● Bottom 40%

Middle

Top 40%

Top 20%

beat the S&P in 22% of quarters+3.8 pts/qtr better · 43% beat rate

That has mattered: over the past 2.7 years, funds with this little specialist backing trailed top-rung funds by about 3.8 points per quarter and beat the S&P in only 22% of fund-quarters. If it also charges an active fee, the higher-graded alternatives deserve a look.

2,825 graded funds · 2.7 years of filings, measured as they were published · evidence, not advice

3 funds in the same segment carry an A — members see the names and what they charge. See the alternatives →

The grade scores this fund's specialist share — the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.

Conviction exposure

12.1%

of the book in specialist-converged names

Late-stage weight

27.6%

of the book in Crowded or Fading names

Active share

87.9%

how far it strays from the index

The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.

Inside the book — top names by stage · as of 2026-09-09

Early Conviction
AMZN 1.8%BKNG 1.7%AJG 0.9%+1 locked
Consensus
SCHW 4.2%RTX 4.1%JCI 3.2%+34 locked
Emerging
FDX 2.2%CMCSA 1.9%CTSH 0.6%+1 locked
Crowded
CVS 2.1%GOOG 1.4%CARR 1%+6 locked
Fading
GSK 2.1%CHTR 1.8%CI 1.8%+16 locked

We email you the day it crosses 50% crowded, and where you stand every month.

Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.

The read · what to do with it

Support leaving these positions

CVS 2.1% of the fund · Crowded

GSK 2.1% of the fund · Fading

CHTR 1.8% of the fund · Fading

CI 1.8% of the fund · Fading

FISV 1.6% of the fund · Fading

Where it's genuinely early

FDX 2.2% of the fund · Emerging

CMCSA 1.9% of the fund · Emerging

AMZN 1.8% of the fund · Early Conviction

Read from today's disclosed book. Evidence, not advice.

The evidence base updates this week.

The specialists — not the whales — are already positioned for what comes next. Stop finding out last.

Create your free account

No card required · open the feed in 30 seconds